Every material Form 8-K Acrivon Therapeutics, Inc. has filed with the SEC since May 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Acrivon Therapeutics said it acquired Aqilion AB's oral JAK1 inhibitor ACR-525 (formerly AQ280) and a PKCθ inhibitor preclinical program in an asset purchase, paying an undisclosed cash amount. The company says it has no obligation to make milestone or royalty payments, and a separate agreement ends prior royalty and milestone obligations on ACR-525 owed to LEO Pharma. The filing gives no financial results or deal value, so its effect on shareholders is not quantified.
Acrivon paid undisclosed cash consideration with no future milestone or royalty payments owed to Aqilion
Acrivon, Aqilion and LEO Pharma terminated prior royalty and milestone obligations on ACR-525
Eosinophilic esophagitis is the first potential indication for ACR-525, which is described as Phase 2-ready
Acrivon will host a KOL webcast on November 10, 2026, at 4:00 p.m. ET
Acrivon Therapeutics reported a second-quarter 2026 net loss of $18.0 million, down from $21.0 million a year earlier, as research and development and general and administrative expenses declined. The company said its cash, cash equivalents and investments of $90.0 million are expected to fund operations into the fourth quarter of 2027. The company also reiterated that interim data from the ACR-368 Phase 2b study are expected in the second half of 2026.
Net loss per share was $0.43 for the quarter ended June 30, 2026, versus $0.55 a year earlier.
Research and development expenses were $13.8 million, versus $16.2 million; the company said two ACR-368 milestones achieved in 2025 did not recur in 2026.
General and administrative expenses were $4.8 million, versus $6.5 million, mainly due to lower employee-related expenses, including stock-based compensation.
Cash, cash equivalents and investments totaled $90.0 million as of June 30, 2026.
At its June 17, 2026 annual meeting, Acrivon Therapeutics stockholders approved an amended and restated 2022 Equity Incentive Plan that adds 3,000,000 shares, bringing the total reserve to 8,606,723 shares. They also re-elected two Class I directors, ratified PricewaterhouseCoopers LLP as auditor for 2026, and the plan's share reserve will rise automatically each January 1 through 2032. The plan allows equity awards to employees, non-employee directors and consultants, so the larger reserve affects the potential share count for existing holders.
Equity plan: total reserve of 8,606,723 shares, including a 3,000,000-share increase; approved with 20,546,400 for and 3,757,400 against
Annual automatic increase on January 1 through 2032 equal to 5% of fully diluted shares outstanding (including pre-funded warrants) at the prior December 31, unless the Board sets a lower amount
Directors: Michael Tomsicek (24,020,408 for) and Charles Baum (23,657,074 for) elected as Class I directors until the 2029 annual meeting
Quorum of 31,336,993.43 shares, or 73.21% of shares entitled to vote as of the April 23, 2026 record date
Acrivon Therapeutics reported a first-quarter 2026 net loss of $19.0 million, or $0.49 per share, compared with $19.7 million, or $0.51 per share, a year earlier. Lower general and administrative expenses offset flat research and development spending, and the company said its cash is expected to fund operations into the third quarter of 2027.
Net loss for the quarter ended March 31, 2026 was $19.0 million, versus $19.7 million a year earlier; net loss per share was $0.49, versus $0.51.
General and administrative expenses fell to $4.7 million from $6.2 million, mainly due to lower employee-related expenses including stock-based compensation.
Research and development expenses were $15.2 million, versus $15.4 million a year earlier.
Cash, cash equivalents and marketable securities were $97.7 million at March 31, 2026, plus $7.3 million in proceeds from subsequent equity financing.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Acrivon Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →